ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Following its September 2011 acquisition of the Swiss drugmaker Nycomed, Takeda Pharmaceutical is embarking on a restructuring program that will cut 2,800 jobs, or 9% of its workforce, across R&D, commercial, operations, and administrative functions. About 2,100 of the jobs to be eliminated are in Europe, and the balance are in the U.S. The Japanese company says it will also consolidate R&D and other sites across the globe. Takeda expects the plan to cost more than $900 million through 2015 but save $2.6 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X